Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005033 · ClinicalTrials.gov registry record · Phase 2
Trastuzumab in Treating Patients With Recurrent Osteosarcoma
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00005033: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00005033 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005033, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of trastuzumab in treating patients who have recurrent osteosarcoma.
Interventions
- BIOLOGICAL trastuzumab
- PROCEDURE conventional surgery
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-12 |
| Est. Completion | 2004-08 |
| Phase | Phase 2 |
What the finished NCT00005033 record still lists
NCT00005033 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which trastuzumab is the first listed.
NCT00005033 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005033 about?
NCT00005033 is a clinical study titled "Trastuzumab in Treating Patients With Recurrent Osteosarcoma". RATIONALE: Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of trastuzumab in treating patients who have recurrent osteosarcoma.
What is the current status of trial NCT00005033?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-12. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00005033?
The interventions under investigation include: trastuzumab (BIOLOGICAL), conventional surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00005033?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia